Companies › Nuevocor Pte.
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Mar 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NVC-001 Gene therapy targeting LMNA mutations | LMNA | Phase 1 | LMNA-Related Dilated Cardiomyopathy | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07606274 | NVC-001 | Phase 1 | LMNA-Related Dilated Cardiomyopathy | Cardiovascular | Mar 2030 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.